ONTOLOGY REPORT - ANNOTATIONS
| Term: | carbamazepine |
|
| Accession: | CHEBI:3387
|
browse the term
|
| Definition: | A dibenzoazepine that is 5H-dibenzo[b,f]azepine carrying a carbamoyl substituent at the azepine nitrogen, used as an anticonvulsant. |
| Synonyms: | exact_synonym: | 5H-dibenzo[b,f]azepine-5-carboxamide |
| | related_synonym: | 5-Carbamoyl-5H-dibenz(b,f)azepine; 5-Carbamoyl-5H-dibenzo(b,f)azepine; 5-Carbamyl-5H-dibenzo(b,f)azepine; 5H-Dibenz(b,f)azepine-5-carboxamide; C15H12N2O; Carbamazepen; InChI=1S/C15H12N2O/c16-15(18)17-13-7-3-1-5-11(13)9-10-12-6-2-4-8-14(12)17/h1-10H,(H2,16,18); InChIKey=FFGPTBGBLSHEPO-UHFFFAOYSA-N; NC(=O)N1c2ccccc2C=Cc2ccccc12; carbamazepina; carbamazepinum |
| | alt_id: | CHEBI:115086 |
| | xref_casrn: | 298-46-4 |
| | xref: | Beilstein:1246090 "Beilstein Registry Number"; ChEMBL:10411478 "PubMed citation"; ChEMBL:115086 "ChEMBL COMPOUND"; ChemIDplus:298-46-4 "CAS Registry Number"; CiteXplore:11071486 "PubMed citation"; CiteXplore:11129121 "PubMed citation"; CiteXplore:11240598 "PubMed citation"; CiteXplore:11475584 "PubMed citation"; CiteXplore:11595204 "PubMed citation"; CiteXplore:11888243 "PubMed citation"; CiteXplore:11891095 "PubMed citation"; CiteXplore:12073283 "PubMed citation"; CiteXplore:12228880 "PubMed citation"; CiteXplore:12475188 "PubMed citation"; CiteXplore:12749779 "PubMed citation"; CiteXplore:12799799 "PubMed citation"; CiteXplore:12957643 "PubMed citation"; CiteXplore:14160216 "PubMed citation"; CiteXplore:14572037 "PubMed citation"; CiteXplore:14581052 "PubMed citation"; CiteXplore:14713026 "PubMed citation"; CiteXplore:14723323 "PubMed citation"; CiteXplore:15165631 "PubMed citation"; CiteXplore:15557493 "PubMed citation"; CiteXplore:15665743 "PubMed citation"; CiteXplore:15683742 "PubMed citation"; CiteXplore:15739418 "PubMed citation"; CiteXplore:15820347 "PubMed citation"; CiteXplore:15850602 "PubMed citation"; CiteXplore:16033627 "PubMed citation"; CiteXplore:16150575 "PubMed citation"; CiteXplore:16245817 "PubMed citation"; CiteXplore:16380297 "PubMed citation"; CiteXplore:16394456 "PubMed citation"; CiteXplore:16437428 "PubMed citation"; CiteXplore:16538175 "PubMed citation"; CiteXplore:16562645 "PubMed citation"; CiteXplore:16616830 "PubMed citation"; CiteXplore:16990009 "PubMed citation"; CiteXplore:17027750 "PubMed citation"; CiteXplore:17028629 "PubMed citation"; CiteXplore:17207414 "PubMed citation"; CiteXplore:17582711 "PubMed citation"; CiteXplore:17873967 "PubMed citation"; CiteXplore:17949959 "PubMed citation"; CiteXplore:18163657 "PubMed citation"; CiteXplore:18415623 "PubMed citation"; CiteXplore:18637155 "PubMed citation"; CiteXplore:18652684 "PubMed citation"; CiteXplore:18656520 "PubMed citation"; CiteXplore:18969759 "PubMed citation"; CiteXplore:19135617 "PubMed citation"; CiteXplore:19473818 "PubMed citation"; CiteXplore:19741433 "PubMed citation"; CiteXplore:19921623 "PubMed citation"; CiteXplore:7602118 "PubMed citation"; DrugBank:DB00564 "DrugBank"; KEGG COMPOUND:298-46-4 "CAS Registry Number"; KEGG COMPOUND:C06868 "KEGG COMPOUND"; KEGG DRUG:D00252 "KEGG DRUG" |
| | xref_mesh: | MESH:D002220 |
| | xref: | NIST Chemistry WebBook:298-46-4 "CAS Registry Number"; Patent:US2004220187 "Patent"; Patent:US2007167446 "Patent"; Patent:US2011177136 "Patent"; Patent:US2011245283 "Patent"; Patent:US2948718 "Patent"; Reaxys:1246090 "Reaxys Registry Number"; Wikipedia:Carbamazepine "Wikipedia" |
|
|
carbamazepine
|
| G |
Abca6 |
ATP-binding cassette, subfamily A (ABC1), member 6 |
|
increases expression |
ISO |
10 |
99,626,334 |
99,693,870 |
RGD:6480464 |
CTD |
| G |
Abcb1a |
ATP-binding cassette, sub-family B (MDR/TAP), member 1A |
|
decreases activity |
ISO |
4 |
21,709,855 |
21,796,628 |
RGD:6480464 |
CTD |
| G |
Abcb1a |
ATP-binding cassette, sub-family B (MDR/TAP), member 1A |
|
affects response to substance |
ISO |
4 |
21,709,855 |
21,796,628 |
RGD:6480464 |
CTD |
| G |
Abcb1a |
ATP-binding cassette, sub-family B (MDR/TAP), member 1A |
|
affects response to substance |
ISO |
4 |
21,709,855 |
21,796,628 |
RGD:6480464 |
CTD |
| G |
Abcb1a |
ATP-binding cassette, sub-family B (MDR/TAP), member 1A |
|
affects transport |
ISO |
4 |
21,709,855 |
21,796,628 |
RGD:6480464 |
CTD |
| G |
Abcb1a |
ATP-binding cassette, sub-family B (MDR/TAP), member 1A |
|
increases expression |
ISO |
4 |
21,709,855 |
21,796,628 |
RGD:6480464 |
CTD |
| G |
Abcb1a |
ATP-binding cassette, sub-family B (MDR/TAP), member 1A |
|
increases expression |
ISO |
4 |
21,709,855 |
21,796,628 |
RGD:6480464 |
CTD |
| G |
Abcb1a |
ATP-binding cassette, sub-family B (MDR/TAP), member 1A |
|
multiple interactions |
EXP |
4 |
21,709,855 |
21,796,628 |
RGD:6480464 |
CTD |
| G |
Abcb1a |
ATP-binding cassette, sub-family B (MDR/TAP), member 1A |
|
increases expression |
EXP |
4 |
21,709,855 |
21,796,628 |
RGD:6480464 |
CTD |
| G |
Abcb1a |
ATP-binding cassette, sub-family B (MDR/TAP), member 1A |
|
increases expression |
ISO |
4 |
21,709,855 |
21,796,628 |
RGD:6480464 |
CTD |
| G |
Abcb1a |
ATP-binding cassette, sub-family B (MDR/TAP), member 1A |
|
affects response to substance |
ISO |
4 |
21,709,855 |
21,796,628 |
RGD:6480464 |
CTD |
| G |
Abcb1a |
ATP-binding cassette, sub-family B (MDR/TAP), member 1A |
|
increases expression |
EXP |
4 |
21,709,855 |
21,796,628 |
RGD:6480464 |
CTD |
| G |
Abcb1b |
ATP-binding cassette, subfamily B (MDR/TAP), member 1B |
|
affects abundance |
ISO |
4 |
21,829,489 |
21,912,239 |
RGD:6480464 |
CTD |
| G |
Abcb7 |
ATP-binding cassette, subfamily B (MDR/TAP), member 7 |
|
increases expression |
ISO |
X |
92,280,115 |
92,430,426 |
RGD:6480464 |
CTD |
| G |
Abcc1 |
ATP-binding cassette, subfamily C (CFTR/MRP), member 1 |
|
increases expression |
EXP |
10 |
452,239 |
575,705 |
RGD:6480464 |
CTD |
| G |
Abcc1 |
ATP-binding cassette, subfamily C (CFTR/MRP), member 1 |
|
multiple interactions |
EXP |
10 |
452,239 |
575,705 |
RGD:6480464 |
CTD |
| G |
Abcc2 |
ATP-binding cassette, subfamily C (CFTR/MRP), member 2 |
|
increases expression |
ISO |
|
|
|
RGD:6480464 |
CTD |
| G |
Abcc2 |
ATP-binding cassette, subfamily C (CFTR/MRP), member 2 |
|
affects response to substance |
ISO |
|
|
|
RGD:6480464 |
CTD |
| G |
Abcc2 |
ATP-binding cassette, subfamily C (CFTR/MRP), member 2 |
|
increases expression |
ISO |
|
|
|
RGD:6480464 |
CTD |
| G |
Abcc2 |
ATP-binding cassette, subfamily C (CFTR/MRP), member 2 |
|
multiple interactions |
EXP |
|
|
|
RGD:6480464 |
CTD |
| G |
Abcc2 |
ATP-binding cassette, subfamily C (CFTR/MRP), member 2 |
|
increases expression |
ISO |
|
|
|
RGD:6480464 |
CTD |
| G |
Abcc2 |
ATP-binding cassette, subfamily C (CFTR/MRP), member 2 |
|
increases transport |
ISO |
|
|
|
RGD:6480464 |
CTD |
| G |
Abcc3 |
ATP-binding cassette, subfamily C (CFTR/MRP), member 3 |
|
increases expression |
EXP |
10 |
82,986,552 |
83,030,799 |
RGD:6480464 |
CTD |
| G |
Abcg2 |
ATP-binding cassette, subfamily G (WHITE), member 2 |
|
increases expression |
ISO |
4 |
87,502,584 |
87,560,017 |
RGD:6480464 |
CTD |
| G |
Adrb1 |
adrenoceptor beta 1 |
|
increases expression |
EXP |
1 |
263,025,655 |
263,027,055 |
RGD:6480464 |
CTD |
| G |
Ager |
advanced glycosylation end product-specific receptor |
|
increases expression |
ISO |
20 |
4,250,613 |
4,253,540 |
RGD:6480464 |
CTD |
| G |
Aldh1a1 |
aldehyde dehydrogenase 1 family, member A1 |
|
increases expression |
EXP |
1 |
223,731,675 |
223,773,285 |
RGD:6480464 |
CTD |
| G |
Ar |
androgen receptor |
|
increases expression |
ISO |
X |
85,949,507 |
86,119,199 |
RGD:6480464 |
CTD |
| G |
Ar |
androgen receptor |
|
increases activity |
ISO |
X |
85,949,507 |
86,119,199 |
RGD:6480464 |
CTD |
| G |
Axin2 |
axin 2 |
|
affects expression |
ISO |
10 |
98,294,466 |
98,321,830 |
RGD:6480464 |
CTD |
| G |
Bcl2 |
B-cell CLL/lymphoma 2 |
|
increases expression |
EXP |
13 |
12,730,736 |
12,905,108 |
RGD:6480464 |
CTD |
| G |
Bdnf |
brain-derived neurotrophic factor |
|
increases expression |
EXP |
|
|
|
RGD:6480464 |
CTD |
| G |
Casp3 |
caspase 3 |
|
increases expression |
EXP |
16 |
48,944,226 |
48,962,420 |
RGD:6480464 |
CTD |
| G |
Ccnd1 |
cyclin D1 |
|
multiple interactions |
ISO |
1 |
205,357,235 |
205,366,757 |
RGD:6480464 |
CTD |
| G |
Ccnd1 |
cyclin D1 |
|
decreases expression |
ISO |
1 |
205,357,235 |
205,366,757 |
RGD:6480464 |
CTD |
| G |
Cd151 |
CD151 molecule (Raph blood group) |
|
decreases expression |
EXP |
1 |
201,653,960 |
201,657,967 |
RGD:6480464 |
CTD |
| G |
Chrna2 |
cholinergic receptor, nicotinic, alpha 2 (neuronal) |
|
affects response to substance |
ISO |
15 |
45,570,809 |
45,587,091 |
RGD:6480464 |
CTD |
| G |
Chrna4 |
cholinergic receptor, nicotinic, alpha 4 (neuronal) |
|
affects binding |
ISO |
3 |
170,171,214 |
170,185,998 |
RGD:6480464 |
CTD |
| G |
Chrnb2 |
cholinergic receptor, nicotinic, beta 2 (neuronal) |
|
affects binding |
ISO |
2 |
181,961,373 |
181,969,581 |
RGD:6480464 |
CTD |
| G |
Col2a1 |
collagen, type II, alpha 1 |
|
affects expression |
ISO |
7 |
136,679,219 |
136,707,976 |
RGD:6480464 |
CTD |
| G |
Cp |
ceruloplasmin (ferroxidase) |
|
decreases expression |
EXP |
2 |
105,086,278 |
105,135,367 |
RGD:6480464 |
CTD |
| G |
Cxcl2 |
chemokine (C-X-C motif) ligand 2 |
|
increases expression |
ISO |
14 |
18,677,129 |
18,679,175 |
RGD:6480464 |
CTD |
| G |
Cxcl2 |
chemokine (C-X-C motif) ligand 2 |
|
multiple interactions |
ISO |
14 |
18,677,129 |
18,679,175 |
RGD:6480464 |
CTD |
| G |
Cyb5a |
cytochrome b5 type A (microsomal) |
|
increases expression |
ISO |
18 |
81,415,972 |
81,452,606 |
RGD:6480464 |
CTD |
| G |
Cyp11b2 |
cytochrome P450, family 11, subfamily b, polypeptide 2 |
|
increases expression |
ISO |
7 |
113,043,365 |
113,049,779 |
RGD:6480464 |
CTD |
| G |
Cyp17a1 |
cytochrome P450, family 17, subfamily a, polypeptide 1 |
|
decreases activity |
ISO |
1 |
251,965,458 |
251,971,449 |
RGD:6480464 |
CTD |
| G |
Cyp17a1 |
cytochrome P450, family 17, subfamily a, polypeptide 1 |
|
decreases expression |
ISO |
1 |
251,965,458 |
251,971,449 |
RGD:6480464 |
CTD |
| G |
Cyp1a1 |
cytochrome P450, family 1, subfamily a, polypeptide 1 |
|
increases expression |
EXP |
8 |
61,462,207 |
61,468,237 |
RGD:6480464 |
CTD |
| G |
Cyp1a1 |
cytochrome P450, family 1, subfamily a, polypeptide 1 |
|
increases expression |
ISO |
8 |
61,462,207 |
61,468,237 |
RGD:6480464 |
CTD |
| G |
Cyp1a2 |
cytochrome P450, family 1, subfamily a, polypeptide 2 |
|
increases expression |
ISO |
8 |
61,439,062 |
61,447,861 |
RGD:6480464 |
CTD |
| G |
Cyp1a2 |
cytochrome P450, family 1, subfamily a, polypeptide 2 |
|
decreases expression |
EXP |
8 |
61,439,062 |
61,447,861 |
RGD:6480464 |
CTD |
| G |
Cyp2a3 |
cytochrome P450, family 2, subfamily a, polypeptide 3 |
|
increases expression |
ISO |
1 |
81,944,896 |
81,953,007 |
RGD:6480464 |
CTD |
| G |
Cyp2b1 |
cytochrome P450, family 2, subfamily b, polypeptide 1 |
|
increases expression |
EXP |
1 |
81,266,828 |
81,290,471 |
RGD:6480464 |
CTD |
| G |
Cyp2b2 |
cytochrome P450, family 2, subfamily b, polypeptide 2 |
|
multiple interactions |
ISO |
1 |
81,345,425 |
81,359,415 |
RGD:6480464 |
CTD |
| G |
Cyp2b2 |
cytochrome P450, family 2, subfamily b, polypeptide 2 |
|
increases expression |
EXP |
1 |
81,345,425 |
81,359,415 |
RGD:6480464 |
CTD |
| G |
Cyp2b2 |
cytochrome P450, family 2, subfamily b, polypeptide 2 |
|
increases expression |
ISO |
1 |
81,345,425 |
81,359,415 |
RGD:6480464 |
CTD |
| G |
Cyp2b2 |
cytochrome P450, family 2, subfamily b, polypeptide 2 |
|
increases expression |
ISO |
1 |
81,345,425 |
81,359,415 |
RGD:6480464 |
CTD |
| G |
Cyp2c11 |
cytochrome P450, subfamily 2, polypeptide 11 |
|
affects metabolic processing |
ISO |
1 |
243,281,320 |
243,320,945 |
RGD:6480464 |
CTD |
| G |
Cyp2c11 |
cytochrome P450, subfamily 2, polypeptide 11 |
|
increases expression |
ISO |
1 |
243,281,320 |
243,320,945 |
RGD:6480464 |
CTD |
| G |
Cyp2c11 |
cytochrome P450, subfamily 2, polypeptide 11 |
|
increases activity |
ISO |
1 |
243,281,320 |
243,320,945 |
RGD:6480464 |
CTD |
| G |
Cyp2c79 |
cytochrome P450, family 2, subfamily c, polypeptide 79 |
|
increases expression |
ISO |
1 |
244,400,004 |
244,493,624 |
RGD:6480464 |
CTD |
| G |
Cyp2c79 |
cytochrome P450, family 2, subfamily c, polypeptide 79 |
|
multiple interactions |
ISO |
1 |
244,400,004 |
244,493,624 |
RGD:6480464 |
CTD |
| G |
Cyp2c79 |
cytochrome P450, family 2, subfamily c, polypeptide 79 |
|
increases metabolic processing |
ISO |
1 |
244,400,004 |
244,493,624 |
RGD:6480464 |
CTD |
| G |
Cyp2c79 |
cytochrome P450, family 2, subfamily c, polypeptide 79 |
|
affects metabolic processing |
ISO |
1 |
244,400,004 |
244,493,624 |
RGD:6480464 |
CTD |
| G |
Cyp2c79 |
cytochrome P450, family 2, subfamily c, polypeptide 79 |
|
affects metabolic processing |
ISO |
1 |
244,400,004 |
244,493,624 |
RGD:6480464 |
CTD |
| G |
Cyp2e1 |
cytochrome P450, family 2, subfamily e, polypeptide 1 |
|
decreases expression |
EXP |
1 |
200,918,521 |
200,928,919 |
RGD:6480464 |
CTD |
| G |
Cyp39a1 |
cytochrome P450, family 39, subfamily a, polypeptide 1 |
|
increases expression |
ISO |
9 |
12,926,125 |
13,002,576 |
RGD:6480464 |
CTD |
| G |
Cyp3a2 |
cytochrome P450, family 3, subfamily a, polypeptide 2 |
|
increases expression |
ISO |
12 |
9,517,016 |
9,541,000 |
RGD:6480464 |
CTD |
| G |
Cyp3a2 |
cytochrome P450, family 3, subfamily a, polypeptide 2 |
|
increases metabolic processing |
ISO |
12 |
9,517,016 |
9,541,000 |
RGD:6480464 |
CTD |
| G |
Cyp3a2 |
cytochrome P450, family 3, subfamily a, polypeptide 2 |
|
multiple interactions |
ISO |
12 |
9,517,016 |
9,541,000 |
RGD:6480464 |
CTD |
| G |
Cyp3a2 |
cytochrome P450, family 3, subfamily a, polypeptide 2 |
|
increases expression |
ISO |
12 |
9,517,016 |
9,541,000 |
RGD:6480464 |
CTD |
| G |
Cyp3a2 |
cytochrome P450, family 3, subfamily a, polypeptide 2 |
|
affects metabolic processing |
ISO |
12 |
9,517,016 |
9,541,000 |
RGD:6480464 |
CTD |
| G |
Cyp3a2 |
cytochrome P450, family 3, subfamily a, polypeptide 2 |
|
increases activity |
ISO |
12 |
9,517,016 |
9,541,000 |
RGD:6480464 |
CTD |
| G |
Cyp3a2 |
cytochrome P450, family 3, subfamily a, polypeptide 2 |
|
increases metabolic processing |
ISO |
12 |
9,517,016 |
9,541,000 |
RGD:6480464 |
CTD |
| G |
Cyp3a2 |
cytochrome P450, family 3, subfamily a, polypeptide 2 |
|
multiple interactions |
ISO |
12 |
9,517,016 |
9,541,000 |
RGD:6480464 |
CTD |
| G |
Cyp3a2 |
cytochrome P450, family 3, subfamily a, polypeptide 2 |
|
multiple interactions |
ISO |
12 |
9,517,016 |
9,541,000 |
RGD:6480464 |
CTD |
| G |
Cyp3a2 |
cytochrome P450, family 3, subfamily a, polypeptide 2 |
|
multiple interactions |
ISO |
12 |
9,517,016 |
9,541,000 |
RGD:6480464 |
CTD |
| G |
Cyp3a2 |
cytochrome P450, family 3, subfamily a, polypeptide 2 |
|
multiple interactions |
EXP |
12 |
9,517,016 |
9,541,000 |
RGD:6480464 |
CTD |
| G |
Cyp3a2 |
cytochrome P450, family 3, subfamily a, polypeptide 2 |
|
increases activity |
ISO |
12 |
9,517,016 |
9,541,000 |
RGD:6480464 |
CTD |
| G |
Cyp3a2 |
cytochrome P450, family 3, subfamily a, polypeptide 2 |
|
increases expression |
ISO |
12 |
9,517,016 |
9,541,000 |
RGD:6480464 |
CTD |
| G |
Cyp3a2 |
cytochrome P450, family 3, subfamily a, polypeptide 2 |
|
increases expression |
ISO |
12 |
9,517,016 |
9,541,000 |
RGD:6480464 |
CTD |
| G |
Cyp3a23/3a1 |
cytochrome P450, family 3, subfamily a, polypeptide 23/polypeptide 1 |
|
increases expression |
EXP |
12 |
9,567,120 |
9,595,974 |
RGD:6480464 |
CTD |
| G |
Cyp3a9 |
cytochrome P450, family 3, subfamily a, polypeptide 9 |
|
increases expression |
ISO |
12 |
17,164,384 |
17,204,589 |
RGD:6480464 |
CTD |
| G |
Cyp4a1 |
cytochrome P450, family 4, subfamily a, polypeptide 1 |
|
decreases expression |
EXP |
5 |
135,901,653 |
135,915,754 |
RGD:6480464 |
CTD |
| G |
Cyp4f18 |
cytochrome P450, family 4, subfamily f, polypeptide 18 |
|
increases expression |
ISO |
16 |
18,183,761 |
18,225,158 |
RGD:6480464 |
CTD |
| G |
Cyp4f6 |
cytochrome P450, family 4, subfamily f, polypeptide 6 |
|
increases expression |
ISO |
7 |
13,609,104 |
13,636,290 |
RGD:6480464 |
CTD |
| G |
Dact1 |
dapper, antagonist of beta-catenin, homolog 1 (Xenopus laevis) |
|
affects expression |
ISO |
6 |
93,402,304 |
93,411,668 |
RGD:6480464 |
CTD |
| G |
Dkk1 |
dickkopf 1 homolog (Xenopus laevis) |
|
affects expression |
ISO |
1 |
234,392,743 |
234,396,426 |
RGD:6480464 |
CTD |
| G |
Drd2 |
dopamine receptor D2 |
|
decreases expression |
EXP |
8 |
52,641,160 |
52,707,749 |
RGD:6480464 |
CTD |
| G |
Enpep |
glutamyl aminopeptidase |
|
increases expression |
EXP |
2 |
226,731,079 |
226,732,069 |
RGD:6480464 |
CTD |
| G |
Eomes |
eomesodermin |
|
affects expression |
ISO |
8 |
123,376,689 |
123,383,451 |
RGD:6480464 |
CTD |
| G |
Epha4 |
Eph receptor A4 |
|
affects expression |
ISO |
9 |
76,676,778 |
76,820,752 |
RGD:6480464 |
CTD |
| G |
Ephx1 |
epoxide hydrolase 1, microsomal (xenobiotic) |
|
increases expression |
ISO |
13 |
96,722,973 |
96,752,940 |
RGD:6480464 |
CTD |
| G |
Ephx1 |
epoxide hydrolase 1, microsomal (xenobiotic) |
|
increases expression |
EXP |
13 |
96,722,973 |
96,752,940 |
RGD:6480464 |
CTD |
| G |
Ephx1 |
epoxide hydrolase 1, microsomal (xenobiotic) |
|
affects response to substance |
ISO |
13 |
96,722,973 |
96,752,940 |
RGD:6480464 |
CTD |
| G |
Ephx2 |
epoxide hydrolase 2, cytoplasmic |
|
decreases expression |
EXP |
15 |
45,497,660 |
45,556,101 |
RGD:6480464 |
CTD |
| G |
Erbb2 |
v-erb-b2 erythroblastic leukemia viral oncogene homolog 2, neuro/glioblastoma derived oncogene homolog (avian) |
|
decreases expression |
ISO |
10 |
87,219,157 |
87,242,919 |
RGD:6480464 |
CTD |
| G |
Erbb2 |
v-erb-b2 erythroblastic leukemia viral oncogene homolog 2, neuro/glioblastoma derived oncogene homolog (avian) |
|
decreases expression |
ISO |
10 |
87,219,157 |
87,242,919 |
RGD:6480464 |
CTD |
| G |
Erbb2 |
v-erb-b2 erythroblastic leukemia viral oncogene homolog 2, neuro/glioblastoma derived oncogene homolog (avian) |
|
multiple interactions |
ISO |
10 |
87,219,157 |
87,242,919 |
RGD:6480464 |
CTD |
| G |
Erbb2 |
v-erb-b2 erythroblastic leukemia viral oncogene homolog 2, neuro/glioblastoma derived oncogene homolog (avian) |
|
affects expression |
ISO |
10 |
87,219,157 |
87,242,919 |
RGD:6480464 |
CTD |
| G |
Esr1 |
estrogen receptor 1 |
|
multiple interactions |
ISO |
1 |
35,523,680 |
35,759,891 |
RGD:6480464 |
CTD |
| G |
Esr1 |
estrogen receptor 1 |
|
decreases expression |
ISO |
1 |
35,523,680 |
35,759,891 |
RGD:6480464 |
CTD |
| G |
Esr1 |
estrogen receptor 1 |
|
increases expression |
ISO |
1 |
35,523,680 |
35,759,891 |
RGD:6480464 |
CTD |
| G |
F10 |
coagulation factor X |
|
decreases expression |
EXP |
16 |
81,327,237 |
81,346,544 |
RGD:6480464 |
CTD |
| G |
Fads2 |
fatty acid desaturase 2 |
|
decreases expression |
ISO |
1 |
212,512,691 |
212,542,622 |
RGD:6480464 |
CTD |
| G |
Faslg |
Fas ligand (TNF superfamily, member 6) |
|
increases expression |
ISO |
13 |
77,472,950 |
77,480,210 |
RGD:6480464 |
CTD |
| G |
Fos |
FBJ osteosarcoma oncogene |
|
multiple interactions |
EXP |
6 |
109,559,135 |
109,562,001 |
RGD:6480464 |
CTD |
| G |
Fos |
FBJ osteosarcoma oncogene |
|
decreases expression |
EXP |
6 |
109,559,135 |
109,562,001 |
RGD:6480464 |
CTD |
| G |
Foxa1 |
forkhead box A1 |
|
affects expression |
ISO |
6 |
77,976,384 |
78,009,176 |
RGD:6480464 |
CTD |
| G |
Foxa2 |
forkhead box A2 |
|
affects expression |
ISO |
3 |
136,739,009 |
136,743,204 |
RGD:6480464 |
CTD |
| G |
Fzd8 |
frizzled family receptor 8 |
|
affects expression |
ISO |
17 |
65,968,739 |
65,971,724 |
RGD:6480464 |
CTD |
| G |
G6pc |
glucose-6-phosphatase, catalytic subunit |
|
decreases expression |
EXP |
10 |
90,393,531 |
90,403,485 |
RGD:6480464 |
CTD |
| G |
Gabra1 |
gamma-aminobutyric acid (GABA) A receptor, alpha 1 |
|
multiple interactions |
EXP |
10 |
27,258,813 |
27,313,725 |
RGD:6480464 |
CTD |
| G |
Gabra1 |
gamma-aminobutyric acid (GABA) A receptor, alpha 1 |
|
increases activity |
EXP |
10 |
27,258,813 |
27,313,725 |
RGD:6480464 |
CTD |
| G |
Gabra2 |
gamma-aminobutyric acid (GABA) A receptor, alpha 2 |
|
increases activity |
EXP |
14 |
39,568,677 |
39,705,897 |
RGD:6480464 |
CTD |
| G |
Gabra5 |
gamma-aminobutyric acid (GABA) A receptor, alpha 5 |
|
multiple interactions |
EXP |
1 |
108,843,086 |
108,955,130 |
RGD:6480464 |
CTD |
| G |
Gabrd |
gamma-aminobutyric acid (GABA) A receptor, delta |
|
multiple interactions |
EXP |
5 |
172,203,064 |
172,214,960 |
RGD:6480464 |
CTD |
| G |
Gap43 |
growth associated protein 43 |
|
affects expression |
ISO |
11 |
59,989,085 |
60,083,971 |
RGD:6480464 |
CTD |
| G |
Gfra3 |
GDNF family receptor alpha 3 |
|
affects expression |
ISO |
18 |
27,167,576 |
27,195,848 |
RGD:6480464 |
CTD |
| G |
Gli2 |
GLI family zinc finger 2 |
|
affects expression |
ISO |
13 |
31,551,089 |
31,607,264 |
RGD:6480464 |
CTD |
| G |
Glul |
glutamate-ammonia ligase |
|
decreases activity |
ISO |
|
|
|
RGD:6480464 |
CTD |
| G |
Grik2 |
glutamate receptor, ionotropic, kainate 2 |
|
decreases expression |
ISO |
20 |
53,231,473 |
53,713,131 |
RGD:6480464 |
CTD |
| G |
Gsta1 |
glutathione S-transferase alpha 1 |
|
increases expression |
ISO |
9 |
20,051,501 |
20,068,146 |
RGD:6480464 |
CTD |
| G |
Gsta2 |
glutathione S-transferase alpha 2 |
|
increases expression |
EXP |
8 |
83,299,249 |
83,312,958 |
RGD:6480464 |
CTD |
| G |
Gstm1 |
glutathione S-transferase mu 1 |
|
increases response to substance |
ISO |
2 |
203,575,444 |
203,580,821 |
RGD:6480464 |
CTD |
| G |
Gstm1 |
glutathione S-transferase mu 1 |
|
increases expression |
EXP |
2 |
203,575,444 |
203,580,821 |
RGD:6480464 |
CTD |
| G |
Gstm2 |
glutathione S-transferase mu 2 |
|
increases expression |
EXP |
2 |
203,549,022 |
203,553,380 |
RGD:6480464 |
CTD |
| G |
Gstz1 |
glutathione S-transferase zeta 1 |
|
increases expression |
ISO |
|
|
|
RGD:6480464 |
CTD |
| G |
Hdac3 |
histone deacetylase 3 |
|
decreases activity |
ISO |
18 |
30,857,209 |
30,875,986 |
RGD:6480464 |
CTD |
| G |
Hdac7 |
histone deacetylase 7 |
|
decreases activity |
ISO |
7 |
136,501,738 |
136,523,073 |
RGD:6480464 |
CTD |
| G |
Hes5 |
hairy and enhancer of split 5 (Drosophila) |
|
affects expression |
ISO |
5 |
171,763,869 |
171,764,636 |
RGD:6480464 |
CTD |
| G |
Hhex |
hematopoietically expressed homeobox |
|
affects expression |
ISO |
1 |
241,736,542 |
241,742,129 |
RGD:6480464 |
CTD |
| G |
Hmbs |
hydroxymethylbilane synthase |
|
decreases activity |
ISO |
8 |
47,314,235 |
47,321,604 |
RGD:6480464 |
CTD |
| G |
Hmgb1 |
high mobility group box 1 |
|
increases expression |
ISO |
|
|
|
RGD:6480464 |
CTD |
| G |
Hmgcr |
3-hydroxy-3-methylglutaryl-CoA reductase |
|
decreases expression |
ISO |
2 |
27,127,504 |
27,149,580 |
RGD:6480464 |
CTD |
| G |
Hmgcs1 |
3-hydroxy-3-methylglutaryl-CoA synthase 1 (soluble) |
|
affects expression |
ISO |
2 |
51,737,090 |
51,754,583 |
RGD:6480464 |
CTD |
| G |
Hmox1 |
heme oxygenase (decycling) 1 |
|
increases expression |
EXP |
19 |
13,963,139 |
13,969,960 |
RGD:6480464 |
CTD |
| G |
Hoxb1 |
homeo box B1 |
|
affects expression |
ISO |
10 |
85,098,903 |
85,100,308 |
RGD:6480464 |
CTD |
| G |
Hoxb4 |
homeo box B4 |
|
affects expression |
ISO |
10 |
85,050,695 |
85,053,277 |
RGD:6480464 |
CTD |
| G |
Hsd3b2 |
hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 2 |
|
decreases activity |
ISO |
2 |
193,500,916 |
193,507,633 |
RGD:6480464 |
CTD |
| G |
Hsp90aa1 |
heat shock protein 90, alpha (cytosolic), class A member 1 |
|
decreases expression |
EXP |
6 |
135,413,616 |
135,419,147 |
RGD:6480464 |
CTD |
| G |
Hsp90aa1 |
heat shock protein 90, alpha (cytosolic), class A member 1 |
|
increases expression |
EXP |
6 |
135,413,616 |
135,419,147 |
RGD:6480464 |
CTD |
| G |
Hspa1a |
heat shock protein 1A |
|
affects response to substance |
ISO |
20 |
3,945,716 |
3,959,552 |
RGD:6480464 |
CTD |
| G |
Hspa1l |
heat shock protein 1-like |
|
affects response to substance |
ISO |
|
|
|
RGD:6480464 |
CTD |
| G |
Htr2c |
5-hydroxytryptamine (serotonin) receptor 2C, G protein-coupled |
|
multiple interactions |
EXP |
X |
31,012,921 |
31,244,127 |
RGD:6480464 |
CTD |
| G |
Htr2c |
5-hydroxytryptamine (serotonin) receptor 2C, G protein-coupled |
|
multiple interactions |
EXP |
X |
31,012,921 |
31,244,127 |
RGD:6480464 |
CTD |
| G |
Ifng |
interferon gamma |
|
decreases expression |
ISO |
7 |
57,621,756 |
57,625,792 |
RGD:6480464 |
CTD |
| G |
Igf1 |
insulin-like growth factor 1 |
|
decreases expression |
EXP |
7 |
24,531,669 |
24,605,742 |
RGD:6480464 |
CTD |
| G |
Il12a |
interleukin 12A |
|
decreases expression |
ISO |
2 |
158,710,261 |
158,717,689 |
RGD:6480464 |
CTD |
| G |
Il23a |
Interleukin 23, alpha subunit p19 |
|
increases expression |
ISO |
7 |
1,584,112 |
1,586,226 |
RGD:6480464 |
CTD |
| G |
Il23a |
Interleukin 23, alpha subunit p19 |
|
multiple interactions |
ISO |
7 |
1,584,112 |
1,586,226 |
RGD:6480464 |
CTD |
| G |
Il6 |
interleukin 6 |
|
decreases expression |
ISO |
4 |
456,799 |
461,376 |
RGD:6480464 |
CTD |
| G |
Il6 |
interleukin 6 |
|
multiple interactions |
ISO |
4 |
456,799 |
461,376 |
RGD:6480464 |
CTD |
| G |
Il6 |
interleukin 6 |
|
increases expression |
ISO |
4 |
456,799 |
461,376 |
RGD:6480464 |
CTD |
| G |
Kcnn2 |
potassium intermediate/small conductance calcium-activated channel, subfamily N, member 2 |
|
decreases activity |
EXP |
18 |
39,560,962 |
39,705,037 |
RGD:6480464 |
CTD |
| G |
Ldlr |
low density lipoprotein receptor |
|
decreases expression |
ISO |
8 |
20,824,040 |
20,846,920 |
RGD:6480464 |
CTD |
| G |
Ldlr |
low density lipoprotein receptor |
|
affects expression |
ISO |
8 |
20,824,040 |
20,846,920 |
RGD:6480464 |
CTD |
| G |
Lhx2 |
LIM homeobox 2 |
|
affects expression |
ISO |
3 |
18,129,455 |
18,147,357 |
RGD:6480464 |
CTD |
| G |
Mafb |
v-maf musculoaponeurotic fibrosarcoma oncogene homolog B (avian) |
|
affects expression |
ISO |
3 |
151,116,831 |
151,118,751 |
RGD:6480464 |
CTD |
| G |
Maoa |
monoamine oxidase A |
|
increases expression |
ISO |
X |
17,678,960 |
17,745,908 |
RGD:6480464 |
CTD |
| G |
Maob |
monoamine oxidase B |
|
increases expression |
ISO |
X |
17,553,529 |
17,657,852 |
RGD:6480464 |
CTD |
| G |
Marcks |
myristoylated alanine rich protein kinase C substrate |
|
increases phosphorylation |
EXP |
20 |
41,304,058 |
41,310,104 |
RGD:6480464 |
CTD |
| G |
Me1 |
malic enzyme 1, NADP(+)-dependent, cytosolic |
|
increases expression |
EXP |
8 |
91,839,845 |
91,955,917 |
RGD:6480464 |
CTD |
| G |
Myo6 |
myosin VI |
|
affects expression |
ISO |
8 |
85,203,987 |
85,368,026 |
RGD:6480464 |
CTD |
| G |
Nat1 |
N-acetyltransferase 1 (arylamine N-acetyltransferase) |
|
increases expression |
ISO |
16 |
23,845,894 |
23,876,528 |
RGD:6480464 |
CTD |
| G |
Nat2 |
N-acetyltransferase 2 (arylamine N-acetyltransferase) |
|
increases expression |
ISO |
16 |
23,855,555 |
23,876,531 |
RGD:6480464 |
CTD |
| G |
Ncl |
nucleolin |
|
decreases expression |
EXP |
9 |
85,112,752 |
85,121,276 |
RGD:6480464 |
CTD |
| G |
Nfkb1 |
nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 |
|
multiple interactions |
ISO |
2 |
233,091,013 |
233,187,501 |
RGD:6480464 |
CTD |
| G |
Nos2 |
nitric oxide synthase 2, inducible |
|
increases expression |
EXP |
10 |
65,036,884 |
65,072,453 |
RGD:6480464 |
CTD |
| G |
Nos2 |
nitric oxide synthase 2, inducible |
|
increases expression |
EXP |
10 |
65,036,884 |
65,072,453 |
RGD:6480464 |
CTD |
| G |
Nqo1 |
NAD(P)H dehydrogenase, quinone 1 |
|
increases expression |
EXP |
19 |
37,251,147 |
37,266,040 |
RGD:6480464 |
CTD |
| G |
Nr1i2 |
nuclear receptor subfamily 1, group I, member 2 |
|
multiple interactions |
ISO |
11 |
64,239,918 |
64,276,702 |
RGD:6480464 |
CTD |
| G |
Nr1i2 |
nuclear receptor subfamily 1, group I, member 2 |
|
increases activity |
ISO |
11 |
64,239,918 |
64,276,702 |
RGD:6480464 |
CTD |
| G |
Nr1i2 |
nuclear receptor subfamily 1, group I, member 2 |
|
increases expression |
EXP |
11 |
64,239,918 |
64,276,702 |
RGD:6480464 |
CTD |
| G |
Nr1i2 |
nuclear receptor subfamily 1, group I, member 2 |
|
increases expression |
ISO |
11 |
64,239,918 |
64,276,702 |
RGD:6480464 |
CTD |
| G |
Nr1i2 |
nuclear receptor subfamily 1, group I, member 2 |
|
increases activity |
ISO |
11 |
64,239,918 |
64,276,702 |
RGD:6480464 |
CTD |
| G |
Nr1i3 |
nuclear receptor subfamily 1, group I, member 3 |
|
multiple interactions |
ISO |
13 |
87,104,241 |
87,108,563 |
RGD:6480464 |
CTD |
| G |
Nr1i3 |
nuclear receptor subfamily 1, group I, member 3 |
|
increases expression |
ISO |
13 |
87,104,241 |
87,108,563 |
RGD:6480464 |
CTD |
| G |
Nr1i3 |
nuclear receptor subfamily 1, group I, member 3 |
|
increases expression |
EXP |
13 |
87,104,241 |
87,108,563 |
RGD:6480464 |
CTD |
| G |
Nr1i3 |
nuclear receptor subfamily 1, group I, member 3 |
|
affects response to substance |
ISO |
13 |
87,104,241 |
87,108,563 |
RGD:6480464 |
CTD |
| G |
Nr3c1 |
nuclear receptor subfamily 3, group C, member 1 |
|
increases expression |
ISO |
18 |
32,371,496 |
32,459,145 |
RGD:6480464 |
CTD |
| G |
Nr3c1 |
nuclear receptor subfamily 3, group C, member 1 |
|
multiple interactions |
ISO |
18 |
32,371,496 |
32,459,145 |
RGD:6480464 |
CTD |
| G |
Nr3c1 |
nuclear receptor subfamily 3, group C, member 1 |
|
multiple interactions |
ISO |
18 |
32,371,496 |
32,459,145 |
RGD:6480464 |
CTD |
| G |
Nr3c2 |
nuclear receptor subfamily 3, group C, member 2 |
|
increases expression |
ISO |
19 |
32,527,752 |
32,875,369 |
RGD:6480464 |
CTD |
| G |
Nrp1 |
neuropilin 1 |
|
affects expression |
ISO |
19 |
58,332,004 |
58,487,686 |
RGD:6480464 |
CTD |
| G |
Nrtn |
neurturin |
|
affects expression |
ISO |
|
|
|
RGD:6480464 |
CTD |
| G |
Pax6 |
paired box 6 |
|
decreases expression |
ISO |
3 |
91,127,605 |
91,149,178 |
RGD:6480464 |
CTD |
| G |
Pc |
pyruvate carboxylase |
|
multiple interactions |
EXP |
1 |
207,112,853 |
207,212,737 |
RGD:6480464 |
CTD |
| G |
Pcsk9 |
proprotein convertase subtilisin/kexin type 9 |
|
decreases expression |
ISO |
5 |
127,501,476 |
127,524,289 |
RGD:6480464 |
CTD |
| G |
Pgrmc1 |
progesterone receptor membrane component 1 |
|
increases expression |
EXP |
X |
8,265,543 |
8,273,667 |
RGD:6480464 |
CTD |
| G |
Pitx2 |
paired-like homeodomain 2 |
|
affects expression |
ISO |
2 |
226,581,170 |
226,601,319 |
RGD:6480464 |
CTD |
| G |
Pla2g4a |
phospholipase A2, group IVA (cytosolic, calcium-dependent) |
|
decreases expression |
ISO |
13 |
64,135,729 |
64,280,815 |
RGD:6480464 |
CTD |
| G |
Pla2g4a |
phospholipase A2, group IVA (cytosolic, calcium-dependent) |
|
increases expression |
ISO |
13 |
64,135,729 |
64,280,815 |
RGD:6480464 |
CTD |
| G |
Pla2g4a |
phospholipase A2, group IVA (cytosolic, calcium-dependent) |
|
multiple interactions |
EXP |
13 |
64,135,729 |
64,280,815 |
RGD:6480464 |
CTD |
| G |
Por |
P450 (cytochrome) oxidoreductase |
|
increases expression |
ISO |
12 |
22,078,629 |
22,097,301 |
RGD:6480464 |
CTD |
| G |
Pou3f1 |
POU class 3 homeobox 1 |
|
increases expression |
ISO |
5 |
143,981,547 |
143,984,527 |
RGD:6480464 |
CTD |
| G |
Ppp3ca |
protein phosphatase 3, catalytic subunit, alpha isozyme |
|
decreases expression |
EXP |
2 |
234,130,176 |
234,409,232 |
RGD:6480464 |
CTD |
| G |
Ptprz1 |
protein tyrosine phosphatase, receptor-type, Z polypeptide 1 |
|
affects expression |
ISO |
4 |
49,267,521 |
49,468,692 |
RGD:6480464 |
CTD |
| G |
Rela |
v-rel reticuloendotheliosis viral oncogene homolog A (avian) |
|
multiple interactions |
ISO |
1 |
208,262,669 |
208,273,148 |
RGD:6480464 |
CTD |
| G |
Rest |
RE1-silencing transcription factor |
|
multiple interactions |
ISO |
14 |
33,136,046 |
33,151,142 |
RGD:6480464 |
CTD |
| G |
RT1-CE7 |
RT1 class I, locus CE7 |
|
affects response to substance |
ISO |
20 |
3,410,094 |
3,413,041 |
RGD:6480464 |
CTD |
| G |
RT1-CE7 |
RT1 class I, locus CE7 |
|
affects response to substance |
ISO |
20 |
3,410,094 |
3,413,041 |
RGD:6480464 |
CTD |
| G |
RT1-S3 |
RT1 class Ib, locus S3 |
|
affects response to substance |
ISO |
20 |
2,815,943 |
2,820,644 |
RGD:6480464 |
CTD |
| G |
S100a8 |
S100 calcium binding protein A8 |
|
increases expression |
ISO |
2 |
182,961,994 |
182,962,513 |
RGD:6480464 |
CTD |
| G |
S100a9 |
S100 calcium binding protein A9 |
|
increases expression |
ISO |
2 |
182,985,466 |
182,988,147 |
RGD:6480464 |
CTD |
| G |
Scd |
stearoyl-CoA desaturase (delta-9-desaturase) |
|
decreases expression |
ISO |
1 |
249,358,105 |
249,371,164 |
RGD:6480464 |
CTD |
| G |
Scn1a |
sodium channel, voltage-gated, type I, alpha |
|
affects response to substance |
ISO |
3 |
48,238,528 |
48,364,143 |
RGD:6480464 |
CTD |
| G |
Scn1a |
sodium channel, voltage-gated, type I, alpha |
|
decreases response to substance |
ISO |
3 |
48,238,528 |
48,364,143 |
RGD:6480464 |
CTD |
| G |
Scn1a |
sodium channel, voltage-gated, type I, alpha |
|
affects response to substance |
ISO |
3 |
48,238,528 |
48,364,143 |
RGD:6480464 |
CTD |
| G |
Scn9a |
sodium channel, voltage-gated, type IX, alpha |
|
affects activity |
ISO |
3 |
48,438,725 |
48,518,893 |
RGD:6480464 |
CTD |
| G |
Scn9a |
sodium channel, voltage-gated, type IX, alpha |
|
affects response to substance |
ISO |
3 |
48,438,725 |
48,518,893 |
RGD:6480464 |
CTD |
| G |
Shbg |
sex hormone binding globulin |
|
increases expression |
ISO |
10 |
56,432,474 |
56,435,654 |
RGD:6480464 |
CTD |
| G |
Slc10a1 |
solute carrier family 10 (sodium/bile acid cotransporter family), member 1 |
|
increases expression |
ISO |
6 |
104,735,839 |
104,749,464 |
RGD:6480464 |
CTD |
| G |
Slc16a2 |
solute carrier family 16, member 2 (thyroid hormone transporter) |
|
increases expression |
ISO |
X |
91,700,554 |
91,825,108 |
RGD:6480464 |
CTD |
| G |
Slc19a1 |
solute carrier family 19 (folate transporter), member 1 |
|
decreases expression |
EXP |
20 |
11,984,283 |
12,001,865 |
RGD:6480464 |
CTD |
| G |
Slc19a1 |
solute carrier family 19 (folate transporter), member 1 |
|
multiple interactions |
EXP |
20 |
11,984,283 |
12,001,865 |
RGD:6480464 |
CTD |
| G |
Slc19a1 |
solute carrier family 19 (folate transporter), member 1 |
|
multiple interactions |
EXP |
20 |
11,984,283 |
12,001,865 |
RGD:6480464 |
CTD |
| G |
Slc19a1 |
solute carrier family 19 (folate transporter), member 1 |
|
decreases activity |
EXP |
20 |
11,984,283 |
12,001,865 |
RGD:6480464 |
CTD |
| G |
Slc19a1 |
solute carrier family 19 (folate transporter), member 1 |
|
multiple interactions |
EXP |
20 |
11,984,283 |
12,001,865 |
RGD:6480464 |
CTD |
| G |
Slc19a1 |
solute carrier family 19 (folate transporter), member 1 |
|
multiple interactions |
EXP |
20 |
11,984,283 |
12,001,865 |
RGD:6480464 |
CTD |
| G |
Slc1a1 |
solute carrier family 1 (neuronal/epithelial high affinity glutamate transporter, system Xag), member 1 |
|
multiple interactions |
EXP |
1 |
232,469,746 |
232,549,584 |
RGD:6480464 |
CTD |
| G |
Slc1a1 |
solute carrier family 1 (neuronal/epithelial high affinity glutamate transporter, system Xag), member 1 |
|
increases activity |
EXP |
1 |
232,469,746 |
232,549,584 |
RGD:6480464 |
CTD |
| G |
Slc22a5 |
solute carrier family 22 (organic cation/carnitine transporter), member 5 |
|
decreases expression |
ISO |
10 |
39,311,729 |
39,338,718 |
RGD:6480464 |
CTD |
| G |
Slc22a7 |
solute carrier family 22 (organic anion transporter), member 7 |
|
decreases expression |
EXP |
9 |
9,934,309 |
9,940,107 |
RGD:6480464 |
CTD |
| G |
Slc23a2 |
solute carrier family 23 (nucleobase transporters), member 2 |
|
increases expression |
ISO |
3 |
119,796,376 |
119,886,011 |
RGD:6480464 |
CTD |
| G |
Slc25a15 |
solute carrier family 25 (mitochondrial carrier; ornithine transporter) member 15 |
|
increases expression |
ISO |
16 |
74,280,827 |
74,301,105 |
RGD:6480464 |
CTD |
| G |
Slc38a3 |
solute carrier family 38, member 3 |
|
increases expression |
ISO |
8 |
112,898,405 |
112,914,444 |
RGD:6480464 |
CTD |
| G |
Slc5a5 |
solute carrier family 5 (sodium iodide symporter), member 5 |
|
multiple interactions |
ISO |
16 |
19,046,200 |
19,056,281 |
RGD:6480464 |
CTD |
| G |
Slc6a16 |
solute carrier family 6, member 16 |
|
increases expression |
ISO |
1 |
95,728,395 |
95,740,069 |
RGD:6480464 |
CTD |
| G |
Slco1a2 |
solute carrier organic anion transporter family, member 1A2 |
|
increases expression |
ISO |
4 |
179,790,209 |
179,851,288 |
RGD:6480464 |
CTD |
| G |
Slco1a4 |
solute carrier organic anion transporter family, member 1a4 |
|
increases expression |
ISO |
|
|
|
RGD:6480464 |
CTD |
| G |
Slco1b3 |
solute carrier organic anion transporter family, member 1b3 |
|
increases expression |
ISO |
4 |
179,045,586 |
179,118,680 |
RGD:6480464 |
CTD |
| G |
Slco2b1 |
solute carrier organic anion transporter family, member 2b1 |
|
increases expression |
ISO |
1 |
156,992,492 |
157,028,887 |
RGD:6480464 |
CTD |
| G |
Slitrk5 |
SLIT and NTRK-like family, member 5 |
|
affects expression |
ISO |
15 |
96,407,553 |
96,412,374 |
RGD:6480464 |
CTD |
| G |
Sod2 |
superoxide dismutase 2, mitochondrial |
|
multiple interactions |
EXP |
1 |
41,862,997 |
41,870,327 |
RGD:6480464 |
CTD |
| G |
Spry2 |
sprouty homolog 2 (Drosophila) |
|
affects expression |
ISO |
15 |
90,009,109 |
90,011,940 |
RGD:6480464 |
CTD |
| G |
Srebf2 |
sterol regulatory element binding transcription factor 2 |
|
decreases expression |
ISO |
7 |
120,522,511 |
120,580,212 |
RGD:6480464 |
CTD |
| G |
St13 |
suppression of tumorigenicity 13 |
|
increases expression |
EXP |
7 |
119,694,123 |
119,728,936 |
RGD:6480464 |
CTD |
| G |
Stmn3 |
stathmin-like 3 |
|
affects expression |
ISO |
3 |
170,446,808 |
170,454,900 |
RGD:6480464 |
CTD |
| G |
Sult1a1 |
sulfotransferase family, cytosolic, 1A, phenol-preferring, member 1 |
|
decreases expression |
EXP |
1 |
185,829,205 |
185,832,725 |
RGD:6480464 |
CTD |
| G |
Tac3 |
tachykinin 3 |
|
multiple interactions |
ISO |
7 |
67,717,068 |
67,723,674 |
RGD:6480464 |
CTD |
| G |
Tbx21 |
T-box 21 |
|
decreases expression |
ISO |
10 |
85,817,743 |
85,834,178 |
RGD:6480464 |
CTD |
| G |
Tfap2a |
transcription factor AP-2 alpha |
|
multiple interactions |
EXP |
17 |
30,017,580 |
30,034,852 |
RGD:6480464 |
CTD |
| G |
Tfap2b |
transcription factor AP-2 beta |
|
multiple interactions |
EXP |
9 |
18,052,402 |
18,082,202 |
RGD:6480464 |
CTD |
| G |
Tfap2b |
transcription factor AP-2 beta |
|
decreases activity |
EXP |
9 |
18,052,402 |
18,082,202 |
RGD:6480464 |
CTD |
| G |
Tfap2c |
transcription factor AP-2 gamma |
|
multiple interactions |
EXP |
3 |
163,459,283 |
163,467,166 |
RGD:6480464 |
CTD |
| G |
Tfap2c |
transcription factor AP-2 gamma |
|
decreases activity |
EXP |
3 |
163,459,283 |
163,467,166 |
RGD:6480464 |
CTD |
| G |
Tgfb2 |
transforming growth factor, beta 2 |
|
affects expression |
ISO |
13 |
102,718,703 |
102,818,768 |
RGD:6480464 |
CTD |
| G |
Tgif1 |
TGFB-induced factor homeobox 1 |
|
affects expression |
ISO |
9 |
110,043,164 |
110,052,783 |
RGD:6480464 |
CTD |
| G |
Tkt |
transketolase |
|
increases expression |
EXP |
16 |
5,908,759 |
5,933,695 |
RGD:6480464 |
CTD |
| G |
Tkt |
transketolase |
|
decreases expression |
EXP |
16 |
5,908,759 |
5,933,695 |
RGD:6480464 |
CTD |
| G |
Tlr4 |
toll-like receptor 4 |
|
increases expression |
ISO |
5 |
83,564,100 |
83,577,735 |
RGD:6480464 |
CTD |
| G |
Tnf |
tumor necrosis factor |
|
affects response to substance |
ISO |
20 |
3,661,000 |
3,663,618 |
RGD:6480464 |
CTD |
| G |
Top2b |
topoisomerase (DNA) II beta |
|
affects expression |
ISO |
|
|
|
RGD:6480464 |
CTD |
| G |
Tulp3 |
tubby-like protein 3 |
|
affects expression |
ISO |
4 |
165,334,192 |
165,376,105 |
RGD:6480464 |
CTD |
| G |
Txnrd1 |
thioredoxin reductase 1 |
|
increases expression |
EXP |
7 |
23,055,544 |
23,093,815 |
RGD:6480464 |
CTD |
| G |
Ugdh |
UDP-glucose 6-dehydrogenase |
|
decreases expression |
EXP |
14 |
45,542,781 |
45,570,961 |
RGD:6480464 |
CTD |
| G |
Ugdh |
UDP-glucose 6-dehydrogenase |
|
increases expression |
EXP |
14 |
45,542,781 |
45,570,961 |
RGD:6480464 |
CTD |
| G |
Ugt1a1 |
UDP glucuronosyltransferase 1 family, polypeptide A1 |
|
increases expression |
EXP |
9 |
87,091,241 |
87,098,362 |
RGD:6480464 |
CTD |
| G |
Ugt1a6 |
UDP glucuronosyltransferase 1 family, polypeptide A6 |
|
increases expression |
EXP |
9 |
87,037,154 |
87,098,362 |
RGD:6480464 |
CTD |
| G |
Ugt2b15 |
UDP glucuronosyltransferase 2 family, polypeptide B15 |
|
increases expression |
ISO |
14 |
22,346,334 |
22,366,860 |
RGD:6480464 |
CTD |
| G |
Ugt2b17 |
UDP glucuronosyltransferase 2 family, polypeptide B17 |
|
increases expression |
EXP |
14 |
22,639,182 |
22,650,931 |
RGD:6480464 |
CTD |
| G |
Ugt2b17 |
UDP glucuronosyltransferase 2 family, polypeptide B17 |
|
increases expression |
ISO |
14 |
22,639,182 |
22,650,931 |
RGD:6480464 |
CTD |
| G |
Ugt2b35 |
UDP glucuronosyltransferase 2 family, polypeptide B35 |
|
increases expression |
ISO |
14 |
22,454,256 |
22,493,510 |
RGD:6480464 |
CTD |
| G |
Ulk2 |
Unc-51 like kinase 2 (C. elegans) |
|
affects expression |
ISO |
10 |
47,931,165 |
48,009,986 |
RGD:6480464 |
CTD |
| G |
Vasp |
vasodilator-stimulated phosphoprotein |
|
affects expression |
ISO |
1 |
78,621,494 |
78,636,762 |
RGD:6480464 |
CTD |
| G |
Zbtb16 |
zinc finger and BTB domain containing 16 |
|
affects expression |
ISO |
8 |
51,931,530 |
52,094,813 |
RGD:6480464 |
CTD |
| G |
Zeb2 |
zinc finger E-box binding homeobox 2 |
|
affects expression |
ISO |
3 |
25,513,009 |
25,654,964 |
RGD:6480464 |
CTD |
Term paths to the root
|